Actively Recruiting
Role of Transposable Elements in Septic Immune Aging
Led by University of California, San Francisco · Updated on 2026-01-30
116
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating how levels of transposable elements may influence outcomes in patients with sepsis, focusing on whether these elements accelerate immune system aging, increase mortality, or raise the risk of secondary infections in intensive care unit (ICU) patients. This observational study involves adults diagnosed with sepsis who meet Sepsis 3 Criteria, alongside healthy individuals for comparison. The research is led by the University of California, San Francisco. Participants include adults aged 18 and older admitted to the ICU with sepsis and a SOFA score of at least 2, as well as healthy controls not hospitalized. The study involves collecting blood samples from all participants for RNA and DNA sequencing to analyze genetic factors related to immune aging and infection outcomes. No additional treatments or interventions are provided during the study. During the study, researchers will evaluate immune system aging over six weeks and monitor mortality and secondary infections within 30 days. Blood draws and genetic sequencing form the primary assessments, with ongoing observation of patient health status in the ICU. Participation does not involve extra procedures beyond standard blood collection, and the study is expected to continue until August 2028.
CONDITIONS
Brief Title
Role of Transposable Elements in Septic Immune Aging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Admitted to ICU with sepsis (Sepsis 3 Criteria)
- SOFA score of at least 2 at time of enrollment
You will not qualify if you...
- Patients on organ transplantation immunosuppression
- Patients with preexisting leukopenia
- Cancer patients receiving CAR-T therapy
- Patients under 18 years of age or otherwise deemed pediatric
- Patients with ongoing bleeding diathesis (e.g., DIC, hemorrhagic shock)
- Patients with chronic hemoglobin below 7.0
- Patients who are blood transfusion dependent prior to ICU admission
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 weeks
Participants undergo DNA and RNA sequencing to analyze genetic markers related to immune aging and sepsis.
1 visit (in-person)
Duration - Up to 30 days
Participants are monitored for immune aging and outcomes such as mortality and secondary infections after initial evaluation.
Follow-up visits as needed up to 30 days
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
A
Alexendar R Perez, M.D., Ph.D
M
Matthieu Legrand, M.D., Ph.D
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here